Comparison of pathologic findings between morphologic subtypes of AEL
| Morphologic classification . | PEL . | Erythroid/myeloid subtype: MDS-EB-1 . | Erythroid/myeloid subtype: MDS-EB-2 . | Erythroid/myeloid subtype: AML (not pure erythroid) . | Erythroid/ myeloid subtype: AML with multilineage dysplasia . | Erythroid/myeloid subtype: unknown MDS/AML . |
|---|---|---|---|---|---|---|
| No. of cases | 5 | 3 | 7 | 3 | 2 | 4 |
| Multilineage dysplasia, n/N (%) | 0/5 (0) | 2/3 (67) | 4/7 (57) | 0/3 (0) | 2/2 (100) | 0/4 (0) |
| Age, y | ||||||
| Median | 2.3 | 13.5 | 16.0 | 15.2 | 6.4 | 14.6 |
| Range | 0.5-2.6 | 11.4-16.4 | 1.3-21.0 | 1.0-16.2 | 6.4-6.4 | 9.00-19.0 |
| Male:female ratio | 2:3 | 2:1 | 3:4 | 2:1 | 1:1 | 1:3 |
| Flow cytometry/immunohistochemistry, n/N (%) | ||||||
| CD36 | 1/1 (100) | NA | 1/2 (50) | 1/1 (100) | NA | 1/1 (100) |
| CD71 | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 1/1 (100) | 2/2 (100) |
| Glycophorin A | 3/3 (100) | 1/1 (100) | 2/2 (100) | NA | 0/1 (0) | 2/2 (100) |
| PAS | 2/2 (100) | NA | NA | 1/1 (100) | 1/1 (100) | NA |
| E-cadherin | 1/1 (100) | NA | NA | NA | NA | NA |
| CD4 | 2/3 (67) | 1/2 (50) | 1/2 (50) | 2/2 (100) | 1/1 (100) | NA |
| CD7 | 0/3 (0) | 1/3 (33) | 3/4 (75) | 1/1 (100) | 0/1 (0) | 2/2 (100) |
| CD13 | 2/5 (40) | 3/3 (100) | 5/5 (100) | 2/2 (100) | 1/1 (100) | 3/3 (100) |
| CD33 | 1/4 (25) | 3/3 (100) | 5/5 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| CD34 | 0/4 (0) | 3/3 (100) | 3/5 (80) | NA | 1/1 (100) | 2/3 (67) |
| CD38 | 1/3 (33) | 1/1 (100) | 1/1 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| CD41 | 1/2 (50) | 0/1 (0) | 1/1 (100) | 1/1 (100) | 0/1 (0) | NA |
| CD42b | 1/1 (100) | NA | NA | NA | 0/1 (0) | NA |
| CD61 | 2/2 (100) | 0/2 (0) | 2/3 (66) | 1/1 (100) | 0/1 (0) | NA |
| CD45 | 4/5 (80) | 1/1 (100) | 2/2 (100) | NA | 1/1 (100) | 1/1 (100) |
| CD64 | 0/3 (0) | 0/1 (0) | 1/3 (33) | 2/2 (100) | 0/1 (0) | 1/1 (100) |
| CD117 | 1/5 (20) | 2/2 (100) | 5/6 (83) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| HLA-DR | 3/5 (60) | 3/3 (100) | 2/5 (40) | 1/2 (50) | 1/1 (100) | 4/4 (100) |
| MPO | 0/5 (0) | 3/3 (100) | 2/2 (100) | 2/3 (66) | 1/1 (100) | 1/3 (33) |
| Morphologic classification . | PEL . | Erythroid/myeloid subtype: MDS-EB-1 . | Erythroid/myeloid subtype: MDS-EB-2 . | Erythroid/myeloid subtype: AML (not pure erythroid) . | Erythroid/ myeloid subtype: AML with multilineage dysplasia . | Erythroid/myeloid subtype: unknown MDS/AML . |
|---|---|---|---|---|---|---|
| No. of cases | 5 | 3 | 7 | 3 | 2 | 4 |
| Multilineage dysplasia, n/N (%) | 0/5 (0) | 2/3 (67) | 4/7 (57) | 0/3 (0) | 2/2 (100) | 0/4 (0) |
| Age, y | ||||||
| Median | 2.3 | 13.5 | 16.0 | 15.2 | 6.4 | 14.6 |
| Range | 0.5-2.6 | 11.4-16.4 | 1.3-21.0 | 1.0-16.2 | 6.4-6.4 | 9.00-19.0 |
| Male:female ratio | 2:3 | 2:1 | 3:4 | 2:1 | 1:1 | 1:3 |
| Flow cytometry/immunohistochemistry, n/N (%) | ||||||
| CD36 | 1/1 (100) | NA | 1/2 (50) | 1/1 (100) | NA | 1/1 (100) |
| CD71 | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 1/1 (100) | 2/2 (100) |
| Glycophorin A | 3/3 (100) | 1/1 (100) | 2/2 (100) | NA | 0/1 (0) | 2/2 (100) |
| PAS | 2/2 (100) | NA | NA | 1/1 (100) | 1/1 (100) | NA |
| E-cadherin | 1/1 (100) | NA | NA | NA | NA | NA |
| CD4 | 2/3 (67) | 1/2 (50) | 1/2 (50) | 2/2 (100) | 1/1 (100) | NA |
| CD7 | 0/3 (0) | 1/3 (33) | 3/4 (75) | 1/1 (100) | 0/1 (0) | 2/2 (100) |
| CD13 | 2/5 (40) | 3/3 (100) | 5/5 (100) | 2/2 (100) | 1/1 (100) | 3/3 (100) |
| CD33 | 1/4 (25) | 3/3 (100) | 5/5 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| CD34 | 0/4 (0) | 3/3 (100) | 3/5 (80) | NA | 1/1 (100) | 2/3 (67) |
| CD38 | 1/3 (33) | 1/1 (100) | 1/1 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| CD41 | 1/2 (50) | 0/1 (0) | 1/1 (100) | 1/1 (100) | 0/1 (0) | NA |
| CD42b | 1/1 (100) | NA | NA | NA | 0/1 (0) | NA |
| CD61 | 2/2 (100) | 0/2 (0) | 2/3 (66) | 1/1 (100) | 0/1 (0) | NA |
| CD45 | 4/5 (80) | 1/1 (100) | 2/2 (100) | NA | 1/1 (100) | 1/1 (100) |
| CD64 | 0/3 (0) | 0/1 (0) | 1/3 (33) | 2/2 (100) | 0/1 (0) | 1/1 (100) |
| CD117 | 1/5 (20) | 2/2 (100) | 5/6 (83) | 2/2 (100) | 1/1 (100) | 4/4 (100) |
| HLA-DR | 3/5 (60) | 3/3 (100) | 2/5 (40) | 1/2 (50) | 1/1 (100) | 4/4 (100) |
| MPO | 0/5 (0) | 3/3 (100) | 2/2 (100) | 2/3 (66) | 1/1 (100) | 1/3 (33) |
MPO, myeloperoxidase; NA, not available.